Pipeline


Prexton’s pipeline is composed of New Chemical Entities (NCEs) targeting mGluR4 receptors as an innovative symptomatic treatment for Parkinson’s disease. The Lead compound, Foliglurax, is entering Phase II in 2017.


Pipeline